AlphAIalphai — Financial news for AI agents
Motley FoolNOV 105 min read$KMDA

Kamada (KMDA) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.Monday, Nov. 10, 2025 at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

Original reporting
Motley Fool · https://www.facebook.com/themotleyfool/, Motley Fool Transcribing
Published Nov 10, 2025, 2:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 11, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Kamada (KMDA) Q3 2025 Earnings Call Transcript — source image
Source · www.fool.com
Decision brief

The 30-second read

$KMDABullishMed
01

Why it matters

The positive earnings report could serve as a catalyst for short-term stock appreciation, especially if accompanied by favorable guidance.

02

Market read

The earnings call is highly relevant for investors and traders focusing on biotech and life sciences sectors, with immediate implications for Kamada's stock.

03

What to watch

Broader industry challenges, regulatory risks, or unforeseen operational issues could offset positive earnings impact.

Timing: High; the earnings call occurred recently, providing timely information.

Background

Kamada's Q3 2025 earnings call provides insights into its financial health and strategic direction amid a competitive biotech landscape.

Company-level read

Ticker impact

$KMDABullishMedium confidence
Context

The earnings call transcript provides insights into Kamada's Q3 2025 financial performance and strategic outlook.

Expected impact

Moderate upward movement over the next 1-3 months, contingent on execution of strategic plans.

Evidence & confidence

The earnings report shows favorable financial metrics; however, market reaction may be tempered by broader industry trends and investor sentiment.

Market effects

Sector

Positive sentiment may boost the biotech and life sciences sectors, especially companies with similar profiles.

Regional

Potentially favorable impact on regional biotech markets, particularly in regions where Kamada operates.

Global

Limited; specific to Kamada and its immediate industry, with minimal direct global market effects.

Counterpoint

What could challenge this read

Market may have already priced in the positive earnings, leading to limited upside; potential for short-term volatility.

Key entities

  • Company
    Kamada Ltd.

    A biopharmaceutical company specializing in plasma-derived therapies.

  • Media Outlet
    Motley Fool

    Provider of financial news and analysis.

Read at source← All news

Related articles

AUG 12
$KMDAMed

Kamada Ltd. Q2 2026 Earnings Call Summary

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.

yahoo.com6 min
AUG 12
$KMDAHighAI 9/10

Kamada Ltd.: Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Gui

Kamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.

finanznachrichten.de6 min
JUL 20
$KMDAMedAI 8/10

Kamada jumps on $50m source plasma deal

Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.

globes.co.il2 min
AUG 12
$RKLBMed

U.S. Space Force Awards $615 Million for Space-Based Sensing and Targeting

The U.S. Space Force’s Space Systems Command awarded a second task order under its Space-Based Sensing and Targeting portfolio totaling $615 million, as part of three initial firm-fixed-price other transaction agreements. Awardees include Rocket Lab and STR LLC, plus a third unnamed company. The program aims to diversify vendors and develop airborne moving-target indicator capabilities for the Joint Force.

latimes.com4 min
AUG 12
$ORCLMed

Oracle employees face new layoff threat months after March job cuts

Oracle is preparing another round of layoffs, according to Business Insider citing internal documents and people familiar with the plans. The company cut about 21,000 jobs, or 13%, in fiscal 2026 ended May 31. Oracle says AI adoption may reduce workforce. It invested $55.7B in infrastructure, recorded $1.84B severance, and expects ~$70B capex plus ~$40B more funding.

americanbazaaronline.com5 min